Abstract:Cancer remains a primary threat to human lives. Recently, amplification of tumor-associated reactive oxygen species (ROS) has been used as a boosting strategy to improve tumor therapy. Here, we report on a bone-targeting prodrug mesoporous silica-based nanoreactor for combined photodynamic therapy (PDT) and enhanced chemotherapy for osteosarcoma. Because of surface modification of a bone-targeting biphosphate moiety and the enhanced permeability and retention effect, the formed nanoreactor shows efficient accumulation in osteosarcoma and exhibits long-term retention in the tumor microenvironment. Upon laser irradiation, the loaded photosensitizer chlorin e6 (Ce6) produces in situ ROS, which not only works for PDT but also functions as a trigger for controlled release of doxorubicin (DOX) and doxycycline (DOXY) from the prodrugs based on a thioketal (<i>TK</i>) linkage. The released DOXY further promotes ROS production, thus perpetuating subsequent DOX/DOXY release and ROS burst. The ROS amplification induces long-term high oxidative stress, which increases the sensitivity of the osteosarcoma to chemotherapy, therefore resulting in enhanced tumor cell inhibition and apoptosis. The as-developed nanoreactor with combined PDT and enhanced chemotherapy based on ROS amplification shows significant promise as a potential platform for cancer treatment.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsami.0c08992?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsami.0c08992</a>.1H NMR spectra of TK, DOX-TK, and DOX-TK-DOXY; inverted fluorescence microscopy images and cell apoptosis with TUNEL staining and cell cycle analyses of OS-732 cells; loading contents of Ce6 for /MSN/DOX-TK-DOXY; particle size, UV-vis absorption spectra, and DOX and DOXY release profiles of /MSN/DOX-TK-DOXY; phototriggered intracellular DOX and DOXY release; intracellular ROS production in OS-732 cells; cell apoptosis with TUNEL staining of OS-732 cells treated with /MSN/DOX-TK-DOXY; MTP measurements for /MSN/DOX-TK-DOX; OS-732 cell metabolism after different treatments; body weights of mice bearing OS-732 tumors; ROS analysis in tumor tissues after treatment with /MSN/DOX-TK-DOXY; inner ring tumor microvessel tortuosity and density; HE staining of main organs after treatment; CD31 expression and RT-PCR analyses of tumor vessels; and quantification of DOX and DOXY contents in major organs (<a class="ext-link" href="/doi/suppl/10.1021/acsami.0c08992/suppl_file/am0c08992_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Mitochondria targeted biomimetic platform for chemo/photodynamic combination therapy against osteosarcoma

Mitochondria-targeting graphene oxide nanocomposites for fluorescence imaging-guided synergistic phototherapy of drug-resistant osteosarcoma

Homologous targeting nanoparticles for enhanced PDT against osteosarcoma HOS cells and the related molecular mechanisms

A multifunctional biomimetic nanoplatform for image-guideded photothermal-ferroptotic synergistic osteosarcoma therapy

Microalgae-based Drug Delivery System for Tumor Microenvironment Photo-Modulating and Synergistic Chemo-Photodynamic Therapy of Osteosarcoma

Bone-Targeting Prodrug Mesoporous Silica-Based Nanoreactor with Reactive Oxygen Species Burst for Enhanced Chemotherapy

Novel diketopyrrolopyrrole NIR-II fluorophores and DDR inhibitors for in vivo chemo-photodynamic therapy of osteosarcoma

Biomimetic Targeted Co‐Delivery System Engineered from Genomic Insights for Precision Treatment of Osteosarcoma

High-performance pyrite nano-catalyst driven photothermal/chemodynamic synergistic therapy for Osteosarcoma

Recent advances in nanoagents delivery system-based phototherapy for osteosarcoma treatment

Polydopamine-modified ZIF-8 Nanoparticles As a Drug Carrier for Combined Chemo-Photothermal Osteosarcoma Therapy

Codelivery of anti-CD47 antibody and chlorin e6 using a dual pH-sensitive nanodrug for photodynamic immunotherapy of osteosarcoma

Photodynamic-therapy and Chemotherapy of TPBC-PEG Nanoplatform Encapsulated Triptolide Synergistically Inhibit Primary Osteosarcoma Growth and Pulmonary Metastasis by Activating HIPPO Signaling

Mitochondria-targeting polydopamine-coated nanodrugs for effective photothermal- and chemo-synergistic therapies against lung cancer

Oligopeptide modified ICG/Cisplatin@CaCO 3 for targeted osteosarcoma NIR-II imaging guided multimodal therapy

Doxorubicin-Loaded Microalgal Delivery System for Combined Chemotherapy and Enhanced Photodynamic Therapy of Osteosarcoma

Dual Regulation of Osteosarcoma Hypoxia Microenvironment by a Bioinspired Oxygen Nanogenerator for Precise Single-Laser Synergistic Photodynamic/photothermal/induced Antitumor Immunity Therapy

A Nanodrug Combining CD47 and Sonodynamic Therapy Efficiently Inhibits Osteosarcoma Deterioration.

Mitochondria-targeted nanoplatforms for enhanced photodynamic therapy against hypoxia tumor

Mitochondria-Targeting and Multiresponsive Nanoplatform Based on AIEgens for Synergistic Chemo-Photodynamic Therapy and Enhanced Immunotherapy.

Tumor-targeted biomimetic nanoplatform precisely integrates photodynamic therapy and autophagy inhibition for collaborative treatment of oral cancer